Financhill
Sell
22

CVM Quote, Financials, Valuation and Earnings

Last price:
$0.30
Seasonality move :
15.75%
Day range:
$0.30 - $0.32
52-week range:
$0.29 - $2.39
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.08x
Volume:
583.4K
Avg. volume:
1M
1-year change:
-85.59%
Market cap:
$23.5M
Revenue:
--
EPS (TTM):
-$0.48

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
CVM
CEL-SCI
-- -- -- -- $7.40
AIM
AIM ImmunoTech
$100K -$0.09 -23.08% -53.85% $2.75
IGC
IGC Pharma
$204K -$0.03 3.39% -50% $3.88
NBY
NovaBay Pharmaceuticals
$2.5M -$0.24 14.03% -95.43% $0.85
PLX
Protalix BioTherapeutics
$18.7M -- 476.31% -- $14.50
PTN
Palatin Technologies
-- -$0.42 -100% -67.93% $7.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
CVM
CEL-SCI
$0.30 $7.40 $23.5M -- $0.00 0% --
AIM
AIM ImmunoTech
$0.12 $2.75 $7.4M -- $0.00 0% 31.88x
IGC
IGC Pharma
$0.33 $3.88 $26.7M -- $0.00 0% 19.69x
NBY
NovaBay Pharmaceuticals
$0.63 $0.85 $3.1M -- $0.00 0% 0.07x
PLX
Protalix BioTherapeutics
$2.24 $14.50 $164.9M 121.00x $0.00 0% 3.85x
PTN
Palatin Technologies
$0.79 $7.00 $20.6M -- $0.00 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
CVM
CEL-SCI
-- 1.534 -- --
AIM
AIM ImmunoTech
48.41% 1.568 17.25% 0.71x
IGC
IGC Pharma
2.1% -1.752 0.51% 0.21x
NBY
NovaBay Pharmaceuticals
4.54% 0.646 1.51% 0.75x
PLX
Protalix BioTherapeutics
-- 1.969 -- 1.22x
PTN
Palatin Technologies
-- -1.737 -- 0.99x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
CVM
CEL-SCI
-- -$6.9M -- -- -- -$4.2M
AIM
AIM ImmunoTech
$27K -$4.5M -219.06% -256.33% -9994.29% -$3.3M
IGC
IGC Pharma
$104K -$1.9M -114.2% -116.24% -730.74% -$1.4M
NBY
NovaBay Pharmaceuticals
$1.6M -$1.1M -334.47% -461.38% -44% -$2.1M
PLX
Protalix BioTherapeutics
$9.6M $4M -19.69% -29.54% 23.06% $4M
PTN
Palatin Technologies
-- -$5.1M -- -- -2356.3% -$4.8M

CEL-SCI vs. Competitors

  • Which has Higher Returns CVM or AIM?

    AIM ImmunoTech has a net margin of -- compared to CEL-SCI's net margin of -10571.43%. CEL-SCI's return on equity of -- beat AIM ImmunoTech's return on equity of -256.33%.

    Company Gross Margin Earnings Per Share Invested Capital
    CVM
    CEL-SCI
    -- -$0.11 --
    AIM
    AIM ImmunoTech
    77.14% -$0.06 $5.6M
  • What do Analysts Say About CVM or AIM?

    CEL-SCI has a consensus price target of $7.40, signalling upside risk potential of 2334.21%. On the other hand AIM ImmunoTech has an analysts' consensus of $2.75 which suggests that it could grow by 2270.69%. Given that CEL-SCI has higher upside potential than AIM ImmunoTech, analysts believe CEL-SCI is more attractive than AIM ImmunoTech.

    Company Buy Ratings Hold Ratings Sell Ratings
    CVM
    CEL-SCI
    1 0 0
    AIM
    AIM ImmunoTech
    1 0 0
  • Is CVM or AIM More Risky?

    CEL-SCI has a beta of 0.666, which suggesting that the stock is 33.414% less volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.411, suggesting its less volatile than the S&P 500 by 58.887%.

  • Which is a Better Dividend Stock CVM or AIM?

    CEL-SCI has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CEL-SCI pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CVM or AIM?

    CEL-SCI quarterly revenues are --, which are smaller than AIM ImmunoTech quarterly revenues of $35K. CEL-SCI's net income of -$7.1M is lower than AIM ImmunoTech's net income of -$3.7M. Notably, CEL-SCI's price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CEL-SCI is -- versus 31.88x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CVM
    CEL-SCI
    -- -- -- -$7.1M
    AIM
    AIM ImmunoTech
    31.88x -- $35K -$3.7M
  • Which has Higher Returns CVM or IGC?

    IGC Pharma has a net margin of -- compared to CEL-SCI's net margin of -711.67%. CEL-SCI's return on equity of -- beat IGC Pharma's return on equity of -116.24%.

    Company Gross Margin Earnings Per Share Invested Capital
    CVM
    CEL-SCI
    -- -$0.11 --
    IGC
    IGC Pharma
    40.47% -$0.02 $6.4M
  • What do Analysts Say About CVM or IGC?

    CEL-SCI has a consensus price target of $7.40, signalling upside risk potential of 2334.21%. On the other hand IGC Pharma has an analysts' consensus of $3.88 which suggests that it could grow by 1057.41%. Given that CEL-SCI has higher upside potential than IGC Pharma, analysts believe CEL-SCI is more attractive than IGC Pharma.

    Company Buy Ratings Hold Ratings Sell Ratings
    CVM
    CEL-SCI
    1 0 0
    IGC
    IGC Pharma
    2 0 0
  • Is CVM or IGC More Risky?

    CEL-SCI has a beta of 0.666, which suggesting that the stock is 33.414% less volatile than S&P 500. In comparison IGC Pharma has a beta of 1.213, suggesting its more volatile than the S&P 500 by 21.346%.

  • Which is a Better Dividend Stock CVM or IGC?

    CEL-SCI has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CEL-SCI pays -- of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CVM or IGC?

    CEL-SCI quarterly revenues are --, which are smaller than IGC Pharma quarterly revenues of $257K. CEL-SCI's net income of -$7.1M is lower than IGC Pharma's net income of -$1.8M. Notably, CEL-SCI's price-to-earnings ratio is -- while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CEL-SCI is -- versus 19.69x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CVM
    CEL-SCI
    -- -- -- -$7.1M
    IGC
    IGC Pharma
    19.69x -- $257K -$1.8M
  • Which has Higher Returns CVM or NBY?

    NovaBay Pharmaceuticals has a net margin of -- compared to CEL-SCI's net margin of -49.65%. CEL-SCI's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    CVM
    CEL-SCI
    -- -$0.11 --
    NBY
    NovaBay Pharmaceuticals
    65.26% -$0.60 $1.1M
  • What do Analysts Say About CVM or NBY?

    CEL-SCI has a consensus price target of $7.40, signalling upside risk potential of 2334.21%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 34.9%. Given that CEL-SCI has higher upside potential than NovaBay Pharmaceuticals, analysts believe CEL-SCI is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    CVM
    CEL-SCI
    1 0 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is CVM or NBY More Risky?

    CEL-SCI has a beta of 0.666, which suggesting that the stock is 33.414% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.726, suggesting its less volatile than the S&P 500 by 27.362%.

  • Which is a Better Dividend Stock CVM or NBY?

    CEL-SCI has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CEL-SCI pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CVM or NBY?

    CEL-SCI quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. CEL-SCI's net income of -$7.1M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, CEL-SCI's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CEL-SCI is -- versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CVM
    CEL-SCI
    -- -- -- -$7.1M
    NBY
    NovaBay Pharmaceuticals
    0.07x -- $2.4M -$1.2M
  • Which has Higher Returns CVM or PLX?

    Protalix BioTherapeutics has a net margin of -- compared to CEL-SCI's net margin of 18.02%. CEL-SCI's return on equity of -- beat Protalix BioTherapeutics's return on equity of -29.54%.

    Company Gross Margin Earnings Per Share Invested Capital
    CVM
    CEL-SCI
    -- -$0.11 --
    PLX
    Protalix BioTherapeutics
    53.37% $0.03 $32.4M
  • What do Analysts Say About CVM or PLX?

    CEL-SCI has a consensus price target of $7.40, signalling upside risk potential of 2334.21%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.50 which suggests that it could grow by 547.32%. Given that CEL-SCI has higher upside potential than Protalix BioTherapeutics, analysts believe CEL-SCI is more attractive than Protalix BioTherapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    CVM
    CEL-SCI
    1 0 0
    PLX
    Protalix BioTherapeutics
    0 0 0
  • Is CVM or PLX More Risky?

    CEL-SCI has a beta of 0.666, which suggesting that the stock is 33.414% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.724, suggesting its less volatile than the S&P 500 by 27.611%.

  • Which is a Better Dividend Stock CVM or PLX?

    CEL-SCI has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CEL-SCI pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CVM or PLX?

    CEL-SCI quarterly revenues are --, which are smaller than Protalix BioTherapeutics quarterly revenues of $18M. CEL-SCI's net income of -$7.1M is lower than Protalix BioTherapeutics's net income of $3.2M. Notably, CEL-SCI's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 121.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CEL-SCI is -- versus 3.85x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CVM
    CEL-SCI
    -- -- -- -$7.1M
    PLX
    Protalix BioTherapeutics
    3.85x 121.00x $18M $3.2M
  • Which has Higher Returns CVM or PTN?

    Palatin Technologies has a net margin of -- compared to CEL-SCI's net margin of -2357.27%. CEL-SCI's return on equity of -- beat Palatin Technologies's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CVM
    CEL-SCI
    -- -$0.11 --
    PTN
    Palatin Technologies
    -- -$0.12 -$111.5K
  • What do Analysts Say About CVM or PTN?

    CEL-SCI has a consensus price target of $7.40, signalling upside risk potential of 2334.21%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 785.18%. Given that CEL-SCI has higher upside potential than Palatin Technologies, analysts believe CEL-SCI is more attractive than Palatin Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    CVM
    CEL-SCI
    1 0 0
    PTN
    Palatin Technologies
    0 0 0
  • Is CVM or PTN More Risky?

    CEL-SCI has a beta of 0.666, which suggesting that the stock is 33.414% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.793, suggesting its less volatile than the S&P 500 by 20.66%.

  • Which is a Better Dividend Stock CVM or PTN?

    CEL-SCI has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CEL-SCI pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CVM or PTN?

    CEL-SCI quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. CEL-SCI's net income of -$7.1M is lower than Palatin Technologies's net income of -$2.4M. Notably, CEL-SCI's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CEL-SCI is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CVM
    CEL-SCI
    -- -- -- -$7.1M
    PTN
    Palatin Technologies
    -- -- $350K -$2.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Qualcomm Stock: 5G Leader at a Bargain Price?
Qualcomm Stock: 5G Leader at a Bargain Price?

Chip giant QUALCOMM Incorporated (NASDAQ:QCOM) was the ultimate chip company…

What Is Buffett Buying and Selling Now?
What Is Buffett Buying and Selling Now?

In Q4 of last year, Warren Buffett made a few…

3 Safest Stocks to Buy Now
3 Safest Stocks to Buy Now

With the S&P 500 now in correction and stocks selling…

Stock Ideas

Buy
52
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $3T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
59
GRRR alert for Mar 15

Gorilla Technology Group [GRRR] is up 29.72% over the past day.

Sell
49
SMTC alert for Mar 15

Semtech [SMTC] is up 21.28% over the past day.

Buy
62
PLPC alert for Mar 15

Preformed Line Products [PLPC] is up 17.38% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock